Melanotan II vs Melanotan I: Skin Research and Beyond

Both Melanotan I (afamelanotide) and Melanotan II are synthetic analogs of alpha-melanocyte stimulating hormone (α-MSH), but they differ significantly in selectivity and duration of action.

Melanotan I is a selective agonist of the MC1R receptor, primarily associated with melanin production in skin melanocytes. It has received FDA approval for erythropoietic protoporphyria (EPP), validating its melanogenic effects in clinical settings.

Melanotan II is less selective, binding to multiple melanocortin receptors (MC1R, MC3R, MC4R, MC5R). This broader binding profile produces additional effects beyond melanogenesis, including potential influence on appetite and sexual function.

The primary research interest in both compounds centers on melanogenesis: increasing melanin production to provide natural photoprotection against UV damage. Studies show measurable increases in skin pigmentation with both variants.

Melanotan I has been studied for rare genetic conditions involving extreme photosensitivity (EPP). Its clinical validation provides stronger evidence base for photoprotection claims, though recreational use remains off-label.

Melanotan II research has expanded to include potential metabolic and neuroendocrine effects due to its broader receptor binding. However, these applications remain experimental with limited human evidence.

Both compounds are administered subcutaneously, typically with a loading phase followed by maintenance dosing. Melanotan I requires more frequent administration due to shorter half-life, while Melanotan II has longer duration.

Nausea and facial flushing are commonly reported across both compounds. Melanotan II users more frequently report appetite suppression and increased libido due to MC4R/MC3R engagement.

Long-term safety data for non-prescription use remains limited. Moles may darken, existing nevi should be monitored, and any suspicious skin changes warrant medical evaluation independent of research context.

While Melanotan I holds FDA approval for EPP, both compounds are unapproved for cosmetic tanning or general wellness applications. Supply chains for "research" versions exist in legal gray areas with variable quality control.

Research protocols should prioritize safety monitoring, including dermatological assessments and documentation of any skin changes. Periodic photography of existing moles helps track potential concerning developments.